Indivior Pharmaceuticals, Inc. (INDV) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q2 26	$0.92	$1.15	+25.0%	—	$343M	—
Q1 26	$0.66	$0.96	+45.5%	—	$317M	—
Q4 25	$0.67	$0.82	+22.4%	—	$358M	—
Q3 25	$0.41	$0.72	+75.6%	—	$314M	—
Q2 25	$0.25	$0.51	+104.0%	—	$302M	—
Q1 25	$0.23	$0.41	+78.3%	—	$266M	—
Q4 24	$0.26	$0.32	+23.1%	—	$299M	—
Q3 24	$0.41	$0.54	+31.7%	—	$307M	—
Q2 24	$0.4	-$0.79	-297.5%	—	$299M	—
Q1 24	$0.42	$0.37	-11.9%	—	$284M	—
Q4 23	$0.28	$0.43	+53.6%	—	$293M	—
Q3 23	$0.3	$0.34	+13.3%	—	$271M	—
Q2 23	$0.22	$0.39	+77.3%	—	$276M	—
Q4 16	$0.35	$0.35	0.0%	—	$259M	—
Q3 16	$0.27	$0.5	+85.2%	—	$268M	—
Q2 16	$0.34	$0.55	+61.8%	—	$274M	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY25	—	$1.68	—	—	$1.2B	—
FY24	—	-$0.36	—	—	$1.2B	—
FY23	—	$0.01	—	—	$1.1B	—
FY22	—	-$0.38	—	—	$901M

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$1.1B	$1.1B	$1B	$785M	$647M	$791M	$901M	$1.1B	$1.2B	$1.2B
YoY change	+4.34%	+3.31%	-8.05%	-21.9%	-17.6%	+22.3%	+13.9%	+21.3%	+8.69%	+4.29%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	1.1B	1.1B	1B	785M	647M	791M	901M	1.1B	1.2B	1.2B
Cost of revenue	107M	104M	128M	140M	97M	127M	159M	186M	231M	246M
Gross profit	951M	989M	877M	645M	550M	664M	742M	907M	957M	993M
Gross margin	89.9%	90.5%	87.3%	82.2%	85%	83.9%	82.4%	83%	80.6%	80.1%
Research & development	119M	89M	67M	53M	40M	52M	72M	106M	107M	97M
Selling, general & administrative	664M	688M	476M	395M	649M	431M	763M	811M	618M	634M
Operating expenses	783M	777M	543M	448M	689M	483M	835M	917M	729M	728M
Operating income	149M	193M	316M	178M	-156M	181M	-91M	-8M	228M	265M
Operating margin	14.1%	17.7%	31.4%	22.7%	-24.1%	22.9%	-10.1%	-0.73%	19.2%	21.4%
Non-operating income, net	—	—	—	—	—	—	—	—	—	-3M
Pretax income	98M	137M	278M	180M	-173M	190M	-95M	1M	14M	239M
Income tax	63M	79M	3M	46M	-25M	-15M	-42M	-1M	11M	29M
Net income	35M	58M	275M	134M	-148M	205M	-53M	2M	3M	210M
Net margin	3.31%	5.31%	27.4%	17.1%	-22.9%	25.9%	-5.88%	0.18%	0.25%	16.9%
EBITDA	156M	201M	346M	230M	-123M	206M	-51M	62M	280M	307M
EPS	0.25	0.4	1.9	0.9	-1	1.4	-0.38	0.01	-0.36	1.68
Diluted EPS	0.25	0.4	1.85	0.9	-1	1.35	-0.38	0.01	-0.36	1.64

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	271M	293M	284M	299M	307M	299M	266M	302M	314M	358M	317M	343M
Cost of revenue	46M	51M	46M	93M	69M	23M	44M	52M	83M	67M	40M	50M
Gross profit	225M	242M	238M	206M	238M	276M	222M	250M	231M	291M	277M	293M
Gross margin	83%	82.6%	83.8%	68.9%	77.5%	92.3%	83.5%	82.8%	73.6%	81.3%	87.4%	85.4%
Research & development	18M	29M	28M	27M	22M	31M	22M	21M	33M	21M	16M	12M
Selling, general & administrative	390M	157M	145M	311M	208M	-47M	132M	158M	155M	189M	124M	122M
Operating expenses	408M	186M	173M	338M	234M	-16M	154M	179M	187M	208M	140M	134M
Operating income	-183M	57M	65M	-132M	4M	292M	68M	71M	44M	83M	137M	159M
Operating margin	-67.5%	19.5%	22.9%	-44.1%	1.3%	97.7%	25.6%	23.5%	14%	23.2%	43.2%	46.4%
Non-operating income, net	—	—	—	—	—	—	—	—	—	-2M	-18M	—
Pretax income	-181M	62M	63M	-135M	-1M	88M	59M	62M	37M	81M	115M	160M
Income tax	-46M	8M	16M	-28M	-5M	28M	11M	44M	-5M	-21M	26M	38M
Net income	-135M	54M	47M	-107M	4M	60M	48M	18M	42M	102M	89M	122M
Net margin	-49.8%	18.4%	16.5%	-35.8%	1.3%	20.1%	18%	5.96%	13.4%	28.5%	28.1%	35.6%
EBITDA	-164M	79M	80M	-97M	22M	106M	77M	82M	54M	94M	144M	165M
EPS	-0.98	0.39	0.35	-0.79	0.03	0.07	0.38	0.15	0.34	0.82	0.71	1.02
Diluted EPS	-0.98	0.38	0.34	-0.79	0.03	0.07	0.38	0.14	0.33	0.79	0.69	0.98

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Market cap	511.1M	793.1M	196.3M	75.6M	214.7M	502.5M	3B	2.1B	1.6B	4.5B	4.4B
Enterprise value	354.1M	412.1M	-486.7M	-691.4M	-358.3M	-313.5M	2.4B	2B	1.7B	4.6B	4.5B
Shares outstanding	144M	144.2M	145.4M	145.4M	146.6M	145.7M	139M	137.3M	132.3M	125M	125M

Valuation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
P/E	14.6	13.7	0.71	0.56	—	2.45	—	1K	548.2	21.4	12.8
P/S	0.48	0.73	0.2	0.1	0.33	0.64	3.36	1.92	1.38	3.62	3.18
P/B	-1.73	-3.91	2.97	0.36	2.62	2.48	59.3	—	-4.73	-45.3	-21
EV/EBITDA	2.27	2.05	-1.41	-3.01	2.91	-1.52	-47.2	31.8	6.07	15.1	7.84
EV/Sales	0.33	0.38	-0.48	-0.88	-0.55	-0.4	2.67	1.8	1.43	3.75	3.39
Earnings yield	6.85%	7.31%	140.1%	177.2%	—	40.8%	—	0.1%	0.18%	4.68%	7.79%
FCF yield	72.8%	31.8%	133.4%	190.4%	-91.7%	63.5%	-0.33%	-17.6%	0.3%	-2.1%	1.99%
PEG	—	—	—	—	—	—	—	—	—	—	0.02

Profitability

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Gross margin	89.9%	90.5%	87.3%	82.2%	85%	83.9%	82.4%	83%	80.6%	80.1%	85.4%
Operating margin	14.1%	17.7%	31.4%	22.7%	-24.1%	22.9%	-10.1%	-0.73%	19.2%	21.4%	46.9%
Net margin	3.31%	5.31%	27.4%	17.1%	-22.9%	25.9%	-5.88%	0.18%	0.25%	16.9%	26.7%
ROE	-11.9%	-28.6%	416.7%	64.1%	-180.5%	101%	-103.9%	—	-0.86%	-212.1%	-212.1%
ROA	2.89%	4.02%	17.8%	8.11%	-9.67%	11.2%	-3%	0.1%	0.23%	17.5%	26.4%
ROIC	-11.8%	-14%	-50.7%	-23.7%	31.8%	-29.5%	16.1%	6.25%	-16.7%	408.5%	477.6%
Return on tangible assets	3.36%	4.6%	19.9%	8.89%	-10.5%	12.3%	-3.25%	0.14%	0.23%	17.5%	28.9%

Financial health

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Current ratio	0.96	1.43	1.62	1.83	1.98	1.8	1.24	0.97	0.89	0.71	0.83
Quick ratio	0.92	1.37	1.53	1.73	1.83	1.68	1.12	0.86	0.7	0.54	0.66
Debt / equity	-1.81	-2.37	3.65	1.4	3.48	1.41	5.43	—	-1.08	-3.55	-0.02
Debt / assets	0.44	0.33	0.16	0.18	0.19	0.16	0.16	0.14	0.28	0.29	0.41
Net debt / EBITDA	-1.01	-1.9	-1.97	-3.33	4.66	-3.96	12.1	-2.06	0.2	0.51	0.63
Interest coverage	3.23	4.7	10.9	9.18	-6.21	8.31	-2.28	1.03	1.34	6.31	15.6
Effective tax rate	64.3%	57.7%	1.08%	25.6%	0%	0%	0%	0%	78.6%	12.1%	9.67%

Per share

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Revenue per share	7.35	7.58	6.91	5.4	4.41	5.43	6.48	7.96	8.98	9.91	10.8
EPS (basic)	0.25	0.4	1.9	0.9	-1	1.4	-0.38	0.01	-0.36	1.68	1.68
EPS (diluted)	0.25	0.4	1.85	0.9	-1	1.35	-0.38	0.01	-0.36	1.64	2.79
Book value per share	-2.05	-1.41	0.45	1.44	0.56	1.39	0.37	0	-2.63	-0.79	-1.76
FCF per share	2.58	1.75	1.8	0.99	-1.34	2.19	-0.07	-2.68	0.04	-0.75	-0.9
Cash per share	4.81	5.98	6.35	7.29	5.85	7.57	6.42	2.99	2.42	1.56	1.88
Capex per share	0.14	0.21	0.08	0.05	0.03	0.03	0.04	0.06	0.22	—	—

Capital allocation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Capex / revenue	1.89%	2.74%	1.09%	0.89%	0.62%	0.51%	0.55%	0.73%	2.44%	—	—
Capex / operating cash flow	14.7%	20.8%	4.53%	3.32%	-2.07%	1.89%	-11.6%	-1.77%	7.77%	—	—
Payout ratio	197.1%	—	—	—	—	—	—	—	—	—	0%
Dividend yield	13.5%	—	—	—	—	—	—	—	—	—	—

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	$271M	$293M	$284M	$299M	$307M	$299M	$266M	$302M	$314M	$358M	$317M	$343M
YoY change	+16.8%	+21.1%	+12.3%	+8.33%	+13.3%	+2.05%	-6.34%	+1%	+2.28%	+19.7%	+19.2%	+13.6%

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & short-term investments	692M	863M	924M	1.1B	858M	1.1B	893M	410M	320M	195M
Receivables	205M	257M	269M	192M	179M	202M	220M	254M	254M	253M
Inventory	41M	52M	78M	73M	93M	95M	114M	142M	178M	155M
Total current assets	990M	1.2B	1.3B	1.4B	1.2B	1.4B	1.3B	1.3B	839M	652M
Property, plant & equipment	27M	54M	57M	90M	89M	83M	76M	106M	139M	170M
Goodwill & intangibles	166M	184M	168M	144M	124M	164M	140M	474M	14M	4M
Total assets	1.2B	1.4B	1.5B	1.7B	1.5B	1.8B	1.8B	2B	1.3B	1.2B
Accounts payable	33M	40M	47M	39M	20M	26M	33M	39M	63M	48M
Short-term debt	101M	5M	4M	9M	12M	11M	11M	12M	28M	39M
Total current liabilities	1B	854M	818M	742M	599M	804M	1B	1.3B	939M	914M
Long-term debt	434M	477M	237M	284M	273M	275M	266M	270M	347M	312M
Total liabilities	1.5B	1.6B	1.5B	1.4B	1.4B	1.6B	1.7B	2B	1.7B	1.3B
Shareholders' equity	-295M	-203M	66M	209M	82M	203M	51M	0	-348M	-99M
Total debt	535M	482M	241M	293M	285M	286M	277M	282M	375M	351M
Net debt	-157M	-381M	-683M	-767M	-573M	-816M	-497M	-34M	56M	156M

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Cash & short-term investments	722M	410M	330M	379M	318M	320M	373M	510M	445M	195M	175M	222M
Receivables	245M	254M	249M	259M	251M	254M	243M	240M	259M	253M	273M	271M
Inventory	142M	142M	163M	171M	178M	178M	163M	149M	157M	155M	152M	151M
Total current assets	1.2B	1.3B	796M	864M	799M	839M	883M	951M	922M	652M	667M	725M
Property, plant & equipment	85M	106M	112M	107M	116M	139M	142M	152M	154M	170M	179M	182M
Goodwill & intangibles	436M	474M	460M	436M	380M	14M	7M	7M	2M	4M	2M	2M
Total assets	1.9B	2B	1.5B	1.5B	1.5B	1.3B	1.4B	1.5B	1.4B	1.2B	1.2B	1.2B
Accounts payable	71M	39M	40M	46M	50M	63M	46M	50M	41M	48M	35M	30M
Short-term debt	11M	12M	12M	13M	14M	28M	29M	29M	28M	39M	9M	9M
Total current liabilities	1.2B	1.3B	861M	1B	962M	939M	1B	1.1B	965M	914M	779M	868M
Long-term debt	266M	270M	267M	268M	270M	347M	341M	337M	328M	312M	500M	500M
Total liabilities	1.9B	2B	1.4B	1.7B	1.6B	1.7B	1.7B	1.7B	1.6B	1.3B	1.3B	1.4B
Shareholders' equity	-24M	0	10M	-121M	-167M	-348M	-286M	-258M	-207M	-99M	-144M	-207M
Total debt	277M	282M	279M	281M	284M	375M	370M	366M	356M	351M	509M	509M
Net debt	-333M	-34M	31M	-21M	-4M	56M	-2M	-144M	-89M	156M	334M	287M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income	149M	193M	292M	178M	-156M	213M	-85M	-4M	2M	210M
Depreciation & amortization	—	—	—	—	—	—	—	—	—	20M
Stock-based compensation	10M	16M	15M	3M	8M	11M	16M	22M	24M	26M
Change in working capital	-23M	-65M	-64M	30M	-45M	-12M	26M	-469M	346M	111M
Operating cash flow	136M	144M	243M	211M	-193M	212M	-43M	-451M	373M	-27M
Capital expenditure	-20M	-30M	-11M	-7M	-4M	-4M	-5M	-8M	-29M	—
Investing cash flow	-20M	-30M	-11M	-6M	-4M	-4M	-223M	-53M	70M	1M
Dividends paid	-69M	—	—	—	—	—	—	—	—	—
Share repurchases	—	—	—	—	0	-101M	-90M	-33M	-173M	-11M
Financing cash flow	-147M	-84M	-237M	-4M	-3M	-86M	-91M	-41M	-102M	-25M
Net change in cash	-31M	30M	-5M	201M	-200M	122M	-357M	-545M	341M	-51M
Free cash flow	372M	252M	262M	144M	-197M	319M	-10M	-368M	5M	-94M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Net income	-183M	61M	—	—	-28M	66M	—	—	43M	102M	89M	122M
Depreciation & amortization	—	—	—	—	—	—	—	—	5M	5M	4M	3M
Stock-based compensation	5M	6M	—	—	6M	6M	—	—	7M	5M	9M	11M
Change in working capital	-75M	-367M	—	—	37M	-57M	—	—	-99M	11M	-125M	63M
Operating cash flow	-253M	-300M	—	—	15M	15M	—	—	-39M	-221M	-9M	229M
Capital expenditure	-2M	-4M	—	—	-7M	-16M	—	—	—	—	—	—
Investing cash flow	25M	144M	—	—	34M	10M	—	—	0	0	1M	0
Dividends paid	—	—	—	—	—	—	—	—	—	—	—	—
Share repurchases	0	-22M	—	—	-51M	-51M	—	—	0	0	-126M	-176M
Financing cash flow	1M	-22M	-20M	1M	-51M	-288M	-3M	0	-3M	-3M	28M	-173M
Net change in cash	-227M	-178M	-20M	1M	-2M	-263M	-3M	0	-42M	-224M	20M	56M
Free cash flow	-7M	-299M	—	—	-18M	-21M	—	—	-59M	-245M	-29M	222M

Indivior Pharmaceuticals, Inc. Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement